National Director, Access Case Management

About the role

The National Director, Access Case Management will lead the strategy, development, and execution of the RevMed internal Patient Support Services Patient Access Advocates (Case Manager) HUB Team to support the launch and lifecycle management of Revolution Medicine's approved therapies. This leader will build, manage, and mentor a national Case Manager (CM) team to ensure patients, providers, and accounts receive timely, compliant support navigating access, reimbursement, affordability pathways, and community support resources. This Patient Access Advocate team will be Revolution Medicine employees working in a hybrid model partnering with a third-party HUB to manage the intake, benefits investigation, and Customer Relationship Management (CRM) software. The CM team will work directly with patients, providers, insurance, and other stakeholders to help patients navigate through their insurance coverage, deploy RevMed's (ON)Path™ Patient Support Services programs, and connect patients to additional external resources to help patients overcome access barriers. This role requires a strategic, hands-on leader with deep expertise in oncology patient access and a passion for ensuring no patient is left behind.

Responsibilities

• Leadership & Team Management
• Partner closely with the Director, Patient Access Operations on the performance and processes of RevMed's (ON)Path Patient Support Program.
• Lead and develop a high-performing national team of CMs.
• Manage team accountability, performance metrics, and engagement models.
• Establish clear KPIs for patient access, issue resolution time, documentation quality, and account satisfaction-ensuring all CMs to meet or exceed expectations.
• Drive a culture of urgency, ownership, and patient-centricity through coaching, virtual/remote people management, dashboard reviews, and performance management.
• Build and oversee standardized escalation frameworks with the Field Reimbursement Team (FRDs), specialty pharmacies, non-commercial pharmacy and insurance providers to ensure rapid and compliant issue resolution.
• Maintain visibility into high-priority or at-risk cases, ensuring swift cross-functional engagement and timely resolution.
• Implement and manage data dashboards tracking patient access milestones (timing of contact with patient and providers during each milestone from enrollment to closure of case, benefit verification, PA status, appeals, specialty and noncommercial pharmacy dispense timing).
• Lead, partner with FRD Director, and set expectations for transitioning all EAP patients with urgency upon FDA approval.
• Monitor all patient cases for delays or bottlenecks, ensuring immediate contact with third party HUB and FRD team for follow-up of unresolved cases.
• Enforce rigorous documentation standards to ensure access barriers are tracked, addressed, and compliantly resolved in alignment with a "no patient left behind" mindset.
• Provide coaching, training, and ongoing development to Patient Access Advocates.
• Foster a culture grounded in compliance, customer centricity, urgency, and collaboration.
• Create and manage a "one-team" mindset with other critical access teams, including third-party hub provider, PAP pharmacy, third-party copay provider, FRD Team, and Patient Access leadership.
• Launch Planning & Strategy
• Develop the national HUB CM launch strategy aligned with FRDs, distribution strategies, Market Access, and corporate strategies.
• Partner cross-functionally with FRDs, Patient Services, Trade/Distribution, and other teams as needed to ensure seamless patient initiation and continuity of therapy as prescribed.
• Design and refine Patient Access Advocate role scope, regional standards, KPIs, reporting structures, and rules of engagement.
• Identify and communicate regional challenges and insights to shape b

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience